Underactive Bladder (UAB)- Epidemiology Forecast–2034

Underactive Bladder (UAB)- Epidemiology Forecast–2034

Key Highlights

DelveInsight’s analyst projects that the Total Diagnosed Prevalent Cases of Underactive Bladder (UAB) in the 7MM were ~ 1,795 thousand in 2023 and these cases are going to increase during the forecast period (2024–2034). This increase in growth can be attributed to growing awareness, ultimately leading to an increase in the diagnosed prevalence of UAB.

According to DelveInsight's analysis, approximately 36% of the Total Diagnosed Prevalent Cases of Underactive Bladder (UAB) in the 7MM were in the United States. Our estimations indicate that in 2023, the EU4 and the UK collectively represented nearly 915 thousand diagnosed prevalent cases of UAB.

Gender-specific diagnosed prevalent cases of Underactive Bladder (UAB) showed that males were more affected by UAB than females in the 7MM in 2023. Men are more frequently affected by UAB due to a higher prevalence of prostate-related issues, such as benign prostatic hyperplasia, which can obstruct bladder outflow and impair bladder muscle function.

According to DelveInsight’s model, diagnosed UAB cases in Japan for 2023 were classified into Detrusor Underactivity, Detrusor Hyperactivity with Impaired Contractility (DHIC), and Acontractile Detrusor (AcD). Detrusor Underactivity accounted for the majority with around 132 thousand cases, while AcD represented approximately 60 thousand cases.

DelveInsight’s analysis shows that, in 2023, the neurogenic subtype represented the highest proportion of diagnosed underactive bladder cases in the US, with approximately 385 thousand cases. This was followed by idiopathic cases at 132 thousand, other unspecified cases at 83 thousand, and myogenic cases at 42 thousand.

DelveInsight’s “Underactive Bladder (UAB) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Underactive Bladder (UAB), historical and forecasted epidemiology of Underactive Bladder (UAB) in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Underactive Bladder (UAB) Understanding

Underactive Bladder (UAB) Overview

Underactive bladder (UAB) is a condition characterized by weakened bladder muscle contractions, resulting in incomplete bladder emptying. UAB can arise from various factors, such as nerve injuries, diabetes, aging, and certain medications. Key risk factors include neurological conditions, previous pelvic surgeries, and chronic health issues. The impact of UAB is substantial, often leading to recurring urinary tract infections, possible kidney damage, and a considerably reduced quality of life due to chronic urinary retention and frequent need for catheterization.

Underactive Bladder (UAB) Diagnosis

Diagnosing UAB involves urodynamic testing, bladder scans, and patient history evaluations to assess bladder function, identify incomplete emptying, and determine underlying causes.

Accuracy in diagnosis of UAB remains a significant challenge within the clinical setting, leading to widespread misdiagnosis or underdiagnoses. UAB is often erroneously interpreted as BOO or overactive bladder OAB due to overlapping symptoms. This diagnostic ambiguity significantly hampers the identification and appropriate management of UAB, resulting in inadequate treatment for many patients.

The overlap in clinical presentation—such as urinary frequency, urgency, and hesitancy—between UAB, BOO, and OAB contributes to this confusion. Healthcare providers may mistakenly attribute symptoms to more commonly diagnosed conditions like BOO or OAB, overlooking the possibility of UAB. This misinterpretation is compounded by the lack of standardized diagnostic criteria and tools specifically tailored for UAB, further exacerbating the issue.

Further details related to diagnosis are provided in the report…

Underactive Bladder (UAB) Epidemiology

For the purpose of designing the patient-based model for Underactive Bladder (UAB), the report provides historical as well as forecasted epidemiology segmented by Prevalent Cases of LUTS - Moderate to Severe, Total Diagnosed Prevalent Cases of Underactive Bladder (UAB), Gender-specific Diagnosed Prevalent Cases of Underactive Bladder (UAB), Classification-specific Diagnosed Prevalent Cases of Underactive Bladder (UAB), and Etiology-specific Diagnosed Prevalent Cases of Underactive Bladder (UAB) in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

According to DelveInsight’s analysis, the Total Diagnosed Prevalent Cases of UAB in the US was found to be nearly 642 thousand in 2023 and is estimated to increase with a significant CAGR throughout the forecast period.

As per DelveInsight’s estimates, Japan accounted for nearly 13% of the Total Diagnosed Prevalent Cases of UAB in the 7MM in 2023.

Our analysis estimates that, in 2023, the US recorded 25,610 thousand prevalent cases of moderate to severe lower urinary tract symptoms (LUTS). Of these cases, males accounted for approximately 14,683 thousand, while females represented about 10,926 thousand. This gender distribution highlights LUTS prevalence disparities in the US.

According to DelveInsight’s estimates, the Total Diagnosed Prevalent Cases of UAB in EU4 and the UK were found to be ~915 thousand million in 2023. Throughout the study period, it is anticipated that there will be a substantial increase in cases for all contributing countries. The highest proportion of UAB cases was reported in Germany among these countries, while the least number of cases was found in France.

DelveInsight’s analysis shows that in 2023, gender-specific cases of underactive bladder (UAB) in the US were significantly higher in males, with approximately 167 thousand cases. In contrast, females accounted for nearly 72 thousand cases. This disparity reflects differences in prevalence between genders within the population diagnosed with UAB.

According to DelveInsight's model, US diagnosed cases of underactive bladder (UAB) in 2023 were segmented into categories, with Detrusor Underactivity showing the highest prevalence at roughly 353 thousand cases, followed by Acontractile Detrusor (AcD) with 160 thousand cases.

In Japan, DelveInsight’s analysis for 2023 indicates the neurogenic subtype as the predominant form of diagnosed UAB, totaling around 144 thousand cases, while idiopathic cases followed at about 49 thousand. Other unspecified types had approximately 31 thousand cases, and myogenic types accounted for 15 thousand cases.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Massachusetts General Hospital, Boston; Department of Urologic Surgery, Nashville, Tennessee, US; Department of Child and Adolescent Psychiatry, Saarland University Hospital, Homburg, Germany; Southmead Hospital, United Kingdom; Department of Urology, University Hospital of Rennes, Rennes, France; Department of Urology, Sakurajyuji Hospital, Japan, and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

The report covers a segment of executive summary, descriptive overview of Underactive Bladder (UAB) explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.

Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.

The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.

A detailed review of current challenges in establishing the diagnosis.

Underactive Bladder (UAB) Report Insights

Patient Population

Country-wise Epidemiology Distribution

Prevalent Cases of LUTS - Moderate to Severe

Total Diagnosed Prevalent Cases of Underactive Bladder (UAB)

Gender-specific Diagnosed Prevalent Cases of Underactive Bladder (UAB)

Classification-specific Diagnosed Prevalent Cases of Underactive Bladder (UAB)

Etiology-specific Diagnosed Prevalent Cases of Underactive Bladder (UAB)

Underactive Bladder (UAB) Report Key Strengths

11 years Forecast

The 7MM Coverage

UAB Epidemiology Segmentation

Underactive Bladder (UAB) Report Assessment

Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

What are the disease risk, burdens, and unmet needs of Underactive Bladder (UAB)? What will be the growth opportunities across the 7MM concerning the patient population of Underactive Bladder (UAB)?

What is the historical and forecasted Underactive Bladder (UAB) patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?

Why is the diagnosed prevalent cases of UAB in Japan lower than the US?

Which country has a high patient share for UAB?

Reasons to Buy

Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand the Underactive Bladder (UAB) prevalence cases in varying geographies over the coming years.

A detailed overview of Gender and Age-specific diagnosed prevalence of UAB, along with diagnosed prevalence of UAB Based on etiology.

To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Underactive Bladder (UAB) Epidemiology report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Underactive Bladder (UAB) cases in 2023?

The highest cases of Underactive Bladder (UAB) was found in the Germany among EU4 and the UK in 2023.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Underactive Bladder (UAB) cases in 2023?

The highest cases of Underactive Bladder (UAB) were found in the US among the 7MM in 2023.